3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Recurrence
1
Pancreatic Neoplasms
1
Neoplasm, Residual
1
Leukemia, Myeloid, Acute
1
Carcinoma, Renal Cell
1
Advanced Solid Tumor
1
Interventions
Cyclophosphamide
41
fludarabine
31
Dexamethasone
27
venetoclax
25
Cytarabine
22
Rituximab
16
pembrolizumab
15
fludarabine phosphate
14
Filgrastim
12
Etoposide
12
Lenalidomide
11
Vincristine
10
Gemcitabine
10
Azacitidine
10
pomalidomide
9
Interleukin-2
9
Granulocyte Colony-Stimulating Factor
9
Doxorubicin
9
Calcium Dobesilate
9
carfilzomib
8
Topotecan
8
Nivolumab
8
Methotrexate
8
Everolimus
8
Decitabine
8
Bortezomib
8
Melphalan
7
Cisplatin
7
Vorinostat
6
Injections
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Recurrence
×
CD3 Complex
×
Clear all
NCT03038230
2025-04-06
MCLA-117 in Acute Myelogenous Leukemia
Merus B.V.
Phase 1
Terminated
80 enrolled